News

Video

Tusamitamab Ravtansine Plus Ramucirumab as 2L Therapy or Beyond in Patients With Metastatic NSq NSCLC and High CEACAM5 Expression (CARMEN-LC04)

Author(s):

Grace Dy, MD, presents data from the CARMEN-LC04 study evaluating safety and anti-tumor activity of tusamitamab ravtansine combined with ramucirumab in high CEACAM5-expressing non-squamous cell (NSQ) NSCLC tumors.

Video Player is loading.
Current Time 0:00
Duration 15:27
Loaded: 0%
Stream Type LIVE
Remaining Time 15:27
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
  • en (Main), selected

Newsletter

Stay up to date on the most recent and practice-changing oncology data